Management of Complicated Urinary Tract Infections in Adult Males (EAU 2024)

Classification & General Principles

• All urinary tract infections in adult males are classified as complicated according to the European Association of Urology (EAU) 2024 guidelines. 1
• Recommended treatment duration is 7–14 days, extending to 14 days when prostatitis cannot be excluded. 2
• Urine culture and susceptibility testing must be performed before initiating antimicrobial therapy. 2
• Because males have higher rates of resistant organisms, broader antimicrobial coverage is required compared with uncomplicated female cystitis. 1

Empirical Oral Therapy – First‑Line Agents

• Fluoroquinolones may be used empirically only when local resistance ≤ 10 %. This threshold is supported by the EAU 2024 guidance. [3][4]
• Ciprofloxacin 500–750 mg orally twice daily for 7 days is recommended when the above resistance threshold is met. [3][4]
• Levofloxacin 750 mg orally once daily for 5 days is an alternative first‑line option under the same resistance conditions. [3][4]

Alternative Oral Agents

• Trimethoprim‑sulfamethoxazole 160/800 mg orally twice daily may be used for 7 days if local resistance is < 20 %; some guidelines advise a 14‑day course for males. [2][3]
• Oral cephalosporins are acceptable alternatives:

• When oral cephalosporins are chosen empirically, an initial intravenous dose of ceftriaxone is recommended to ensure adequate early coverage. [3][4]

Indications for Parenteral (IV) Therapy

Recommended IV Regimens

• Ciprofloxacin 400 mg IV twice daily – appropriate when fluoroquinolone resistance is low. [5][6]2
• Levofloxacin 750 mg IV once daily – alternative fluoroquinolone IV option. [5][6]
• Ceftriaxone 1–2 g IV once daily (higher dose preferred for severe infection). [5][6]
• Cefepime 1–2 g IV twice daily – broad‑spectrum β‑lactam for resistant organisms. [5][6]

Specific Considerations & Pitfalls

• Prostatitis suspicion (fever or persistent symptoms) mandates extending therapy to 14 days to ensure adequate prostatic penetration. 2
• Nitrofurantoin and fosfomycin should not be used for pyelonephritis because of insufficient systemic activity. [3][7]
• Local antimicrobial resistance patterns must be reviewed; fluoroquinolones are appropriate only when resistance ≤ 10 %. [3][4]

De‑escalation Strategy

• After culture results are available, switch from IV to oral therapy once the patient is afebrile for ≥ 48 hours and hemodynamically stable. [2][3]
• Narrow the antimicrobial spectrum based on susceptibility data to minimize collateral damage. 2

All facts are derived from cited EAU 2024 guideline statements and associated European Urology references.

Empiric Management and Workup of Complicated Urinary Tract Infections in Adult Males

Initial Assessment and Diagnostic Workup

• Obtain a urine culture with susceptibility testing before any antimicrobial initiation in every adult male presenting with a urinary tract infection. (European Association of Urology) 8
• Collect two sets of blood cultures when fever, systemic signs, or suspected urosepsis are present. (EAU) 8
• If drainage fluid (e.g., from a nephrostomy tube or abscess) is available, send it for culture. (EAU) 8
• Screen for systemic involvement using qSOFA criteria (respiratory rate ≥ 22/min, altered mental status, systolic blood pressure ≤ 100 mmHg); any positive criterion mandates immediate intravenous therapy and source‑control measures. (EAU) 8
• Perform early imaging (renal/abdominal ultrasound or CT) to detect obstruction, stones, or abscesses, especially in recurrent cases or when the patient does not improve with initial therapy. (EAU) 8

Empiric Antimicrobial Therapy

• For males with fever or systemic symptoms, start intravenous ceftriaxone 1–2 g once daily as the preferred first‑line agent for broad coverage. (EAU) 8
• If local fluoroquinolone resistance is ≤ 10 %, intravenous ciprofloxacin (400 mg twice daily) or levofloxacin (750 mg once daily) may be used; otherwise, avoid fluoroquinolones empirically. (EAU) 8
• Do not use fluoroquinolones empirically in patients who work in urology departments or who have received a fluoroquinolone within the past six months, because resistance rates are unacceptably high. (EAU) 8

Management of Urological Abnormalities and Source Control

• Identify and correct any underlying urological abnormality (e.g., obstruction, calculi, indwelling catheter) as part of the treatment plan. (EAU) 8
• Relieve obstruction and drain any urinary‑tract abscess promptly; source control is as critical as antimicrobial therapy in urosepsis. (EAU) 8
• Replace or remove an indwelling catheter before initiating antimicrobial therapy. (EAU) 8

Special Situations: Catheter‑Associated UTI

• Symptomatic catheter‑associated urinary tract infection should be managed according to the same complicated‑UTI recommendations outlined above. (EAU) 8
• Asymptomatic bacteriuria in catheterized patients should not be treated unless a traumatic urological procedure (e.g., transurethral resection of the prostate) is planned. (EAU) 8

Common Pitfalls to Avoid

• Using fluoroquinolones when local resistance exceeds 10 % or in patients with recent fluoroquinolone exposure leads to higher rates of treatment failure. (EAU) 8
• Failing to obtain pre‑treatment cultures deprives clinicians of susceptibility data needed for de‑escalation and for guiding therapy in case of failure. (EAU) 8
• Neglecting source‑control measures (e.g., obstruction relief, abscess drainage) compromises cure rates, even when appropriate antibiotics are given. (EAU) 8

Nitrofurantoin Use and Considerations in Elderly Male Urinary Tract Infections

Therapeutic Recommendation

• Nitrofurantoin 100 mg orally twice daily for 7 days is recommended for lower urinary‑tract infection (cystitis) in elderly male patients when fluoroquinolones are contraindicated or local fluoroquinolone resistance exceeds 10 %. This recommendation applies to patients without signs of upper‑tract involvement. 9

Patient Assessment in Geriatric Populations

• When treating frail or geriatric patients (age > 80 years or with multimorbidity), clinicians should evaluate polypharmacy, potential drug‑drug interactions, and the heightened risk of adverse events before selecting an antibiotic. 9
• Elderly patients frequently present with atypical UTI manifestations—such as altered mental status, functional decline, fatigue, or falls—rather than classic dysuria or frequency. Recognizing these presentations is essential for timely diagnosis and appropriate therapy. 9

Safety Profile of Nitrofurantoin in the Elderly

• Prolonged nitrofurantoin therapy may cause pulmonary toxicity and peripheral neuropathy, particularly in patients with reduced renal function (estimated creatinine clearance < 30 mL/min). Clinicians should monitor renal function and limit duration of therapy accordingly. 9